These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 32483117)
1. Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. Rose JC; Popp NA; Richardson CD; Stephany JJ; Mathieu J; Wei CT; Corn JE; Maly DJ; Fowler DM Nat Commun; 2020 Jun; 11(1):2697. PubMed ID: 32483117 [TBL] [Abstract][Full Text] [Related]
2. CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs. Coelho MA; De Braekeleer E; Firth M; Bista M; Lukasiak S; Cuomo ME; Taylor BJM Nat Commun; 2020 Aug; 11(1):4132. PubMed ID: 32807781 [TBL] [Abstract][Full Text] [Related]
3. Genome Editing with CRISPR-Cas9: Can It Get Any Better? Haeussler M; Concordet JP J Genet Genomics; 2016 May; 43(5):239-50. PubMed ID: 27210042 [TBL] [Abstract][Full Text] [Related]
4. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system. Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359 [TBL] [Abstract][Full Text] [Related]
5. Optimization of genome editing through CRISPR-Cas9 engineering. Zhang JH; Adikaram P; Pandey M; Genis A; Simonds WF Bioengineered; 2016 Apr; 7(3):166-74. PubMed ID: 27340770 [TBL] [Abstract][Full Text] [Related]
6. [CRISPR/CAS9, the King of Genome Editing Tools]. Bannikov AV; Lavrov AV Mol Biol (Mosk); 2017; 51(4):582-594. PubMed ID: 28900076 [TBL] [Abstract][Full Text] [Related]
7. Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. Fu Y; Reyon D; Joung JK Methods Enzymol; 2014; 546():21-45. PubMed ID: 25398334 [TBL] [Abstract][Full Text] [Related]
8. Boosting activity of high-fidelity CRISPR/Cas9 variants using a tRNA He X; Wang Y; Yang F; Wang B; Xie H; Gu L; Zhao T; Liu X; Zhang D; Ren Q; Liu X; Liu Y; Gao C; Gu F J Biol Chem; 2019 Jun; 294(23):9308-9315. PubMed ID: 31010827 [TBL] [Abstract][Full Text] [Related]
9. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field. He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117 [TBL] [Abstract][Full Text] [Related]
10. Target binding and residence: a new determinant of DNA double-strand break repair pathway choice in CRISPR/Cas9 genome editing. Feng Y; Liu S; Chen R; Xie A J Zhejiang Univ Sci B; 2021 Jan; 22(1):73-86. PubMed ID: 33448189 [TBL] [Abstract][Full Text] [Related]